Bildkälla: Stockfoto

Immunicum Q1: Significant catalysts ahead - Redeye

Redeye sees significant news flow for Immunicum in the coming six months, both in clinical development and financing.

Redeye sees significant news flow for Immunicum in the coming six months, both in clinical development and financing.
Börsvärldens nyhetsbrev
ANNONSER